A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.

Chowdhury, Abu Taiub Mohammed Mohiuddin; Shahbaz, Mohammad; Karim, Rezaul; Islam, Johirul; Guo, Dan; He, Shuixiang

doi:10.21203/rs.3.rs-38896/v1

Cited by 45 publications

(54 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chowdhury et al, [29] compare mild / moderate COVID-19 patient group A which received Ivermectin 200 mcg/kg single dose plus Doxy 100mg BID for 10 days, versus group B (56 patients) which received; Hydroxychloroquine (HCQ) 400 mg1st day, then 200mg BID for 9 days plus Azithromycin 500mg daily for 5 Days. The substantial improvement with signi cant reduction in mortality rate in Ivermectin treated groups; group I (mild/moderate cases), (99%, and 0.0%, respectively) and group III (severe cases), (94%, and 2.0% and respectively) versus Hydroxychloroquine treated groups; group II (mild/moderate cases), (74% and 4%, respectively) and group IV (severe cases) (50% and 20%, respectively) highlighted the strong recommendation of its use in COVID -19 management .…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

Elgazzar

Hany

Youssef

et al. 2020

Preprint

166

View full text Add to dashboard Cite

Background: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy "Ivermectin" plus standard care (azithromycin, vitamin C, Zinc, Lactoferrin & Acetylcystein & prophylactic or therapeutic anticoagulation if D-dimer > 1000) in the treatment of mild/moderate and severely ill cases with COVID 19 infection, as well as prophylaxis of health care and/ or household contacts in comparison to the Hydroxychloroquine plus standard treatment. Subject and methods: 600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health care and household contacts distributed over 6 groups; Group I: 100 patients with Mild/Moderate COVID-19 infection received a 4-days course of Ivermectin plus standard of care; Group II: 100 patients with mild/moderate COVID-19 infection received hydroxyxholorquine plus standard of care; Group III: 100 patients with severe COVID-19 infection received Ivermectin plus standard of care; Group IV: 100 patients with Severe COVID-19 infection received hydroxyxholorquine plus standard of care. Routine laboratory investigations and RT-PCR were reported before and after initiation of treatment. Group V stick to personal protective equipment (PPE) plus Ivermectin 400mcg / kg to be repeated after one week, and Group VI stick to PPE only and both groups V&VI were followed for two weeks. Results: Patients received ivermectin reported substantial recovery of laboratory investigations; and significant reduction in RT-PCR conversion days. A substantial improvement and reduction in mortality rate in Ivermectin treated groups; group I (mild/moderate cases), (99%, and 0.0%, respectively) and group III (severe cases), (94%, and 2.0%, respectively) versus hydroxychloroquine plus standard care treated groups; group II (mild/moderate cases), (74% and 4%, respectively) and group IV (severe cases) (50% and 20%, respectively). Ivermectin had significantly reduced the incidence of infection in health care and household contacts up to 2% compared to 10% in non ivermectin group Conclusion: Addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality compared to Hydroxychloroquine plus standard treatment only. Early use of Ivermectin is very useful for controlling COVID 19 infections, prophylaxis and improving cytokines storm

show abstract

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

Elgazzar

Hany

Youssef

et al. 2020

Preprint

166

View full text Add to dashboard Cite

show abstract

“…Chowdhury et al, [29] compare mild / moderate COVID-19 patient group A which received Ivermectin 200 mcg/kg single dose plus Doxy 100mg BID for 10 days, versus group B (56 patients) which received; Hydroxychloroquine (HCQ) 400 mg1st day, then 200mg BID for 9 days plus Azithromycin 500mg daily for 5 Days. Group A versus Group-B: Recovery rate was 100% versus 96.36%, mean symptomatic recovery duration was 5.93 days' versus 6.99 days and negative PCR was achieved on 8.93 days versus 9.33 days, and by 5th day, 55.10% versus 23.8% respectively.…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

Elgazzar

Hany

Youssef

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy "Ivermectin" plus standard care ((Azithromycin, vitamin C, Zinc, Lactoferrin & Acetylcystein & prophylactic or therapeutic anticoagulation if D-dimer > 1000)) in the treatment of mild/moderate and severely ill cases with COVID 19 infection, as well as prophylaxis of health care and/ or household contacts in comparison to the Hydroxychloroquine plus standard treatment.Subject and methods: 600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health care and household contacts distributed over 6 groups; Group I: 100 patients with mild/moderate COVID-19 infection received a 4-days course of Ivermectin plus standard of care; Group II: 100 patients with mild/moderate COVID-19 infection received hydroxychloroquine plus standard of care; Group III: 100 patients with severe COVID-19 infection received Ivermectin plus standard of care; Group IV: 100 patients with Severe COVID-19 infection received hydroxychloroquine plus standard of care. Routine laboratory investigations and RT-PCR, were reported before and after initiation of treatment. Group V stick to PPE plus Ivermectin 400mcg / kg on empty stomach to be repeated after one week, and group VI stick to PPE only (personal protective equipment) .Both groups V&VI were followed for two weeks ..Results: Patients received ivermectin reported substantial recovery of laboratory investigations; and significant reduction in RT-PCR conversion days. A substantial improvement and reduction in mortality rate in Ivermectin treated groups; group I (mild/moderate cases), (99%, and 0.0%, respectively) and group III (severe cases), (94%, and 2.0% respectively) versus hydroxychloroquine plus standard care treated groups; group II (mild/moderate cases), (74% and 4%, respectively) and group IV (severe cases) (50% and 20%, respectively). Ivermectin had significantly reduced the incidence of infection in health care and household contacts up to 2% compared to 10% in non ivermectin group when used as a prophylaxis.Conclusion: Addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality compared to Hydroxychloroquine plus standard treatment only. Early use of Ivermectin is very useful for controlling COVID 19 infections; prophylaxis and improving cytokines storm

show abstract

“… 5 It can be combined with other molecules of interest, like Hydroxychloroquine, azithromycin, doxycycline. 6 Ivermectin is affordable, easily available, and safe without any major side effects. 5 …”

Section: Executive Summarymentioning

confidence: 99%

“…Recently, there have been several observational studies in Bangladesh showing encouraging results in a case series of Covid 19 patients given a combination of Ivermectin and Doxycycline. 6 The combination was tested by Dr. Tarek Alam at the Bangladesh Medical College. 17…”

Section: International Statusmentioning

confidence: 99%

“…Ivermectin–Doxycycline combination therapy has a better success of symptomatic relief; shortened recovery duration, reduced adverse effects, and superior patient compliance compared to the Hydroxychloroquine–Azithromycin combination. 6 INDIA: A study on 2000 patients is ongoing in Max Super Speciallity Hospital (DDF), East Block, Internal Medicine Department, 2- Press Enclave Road, New Delhi. 22 …”

Section: Ongoing Clinical Trials In Various Countriesmentioning

confidence: 99%

See 1 more Smart Citation

White paper on Ivermectin as a potential therapy for COVID-19

Vora¹,

Arora²,

Behera³

et al. 2020

Indian Journal of Tuberculosis

View full text Add to dashboard Cite

A group of senior doctors with vast clinical experience met on 19th July’20 under the aegis of Academy of Advanced Medical Education. The panel looked at Ivermectin, one of the old molecule and evaluated it's use in COVID 19 (Novel Coronavirus Disease 2019) management. After critical panel discussion, all the attending doctors came to a conclusion that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability and good tolerability and safety.

show abstract

A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.

Cited by 45 publications

References 9 publications

WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

White paper on Ivermectin as a potential therapy for COVID-19

Contact Info

Product

Resources

About